Anti-human vista antibodies and use thereof

Patent metadata

Field	Value
Publication number	US-11603402-B2
Application number	US-201715489164-A
Country	US
Kind code	B2
Filing date	Apr 17, 2017
Priority date	Apr 15, 2016
Publication date	Mar 14, 2023
Grant date	Mar 14, 2023

Abstract

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

First claim

The invention claimed is:

1. A method of treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of an isolated antibody comprising an antigen binding region that specifically binds to human V-domain Ig Suppressor of T cell Activation (human VISTA), wherein the antibody comprises a full length human IgG2 Fc region that comprises native binding to human Fc gamma receptors and further comprises a variable heavy chain comprising the CDR polypeptides of SEQ ID NO: 740, 741 and 742 and a variable light chain comprising the CDR polypeptides of SEQ ID NO: 743, 744 and 745 and further wherein the antibody agonizes or promotes one or more of the effects of VISTA on T cell immunity.

2. The method of claim 1 wherein the isolated antibody comprises a variable heavy and/or variable light polypeptide having at least 90% sequence identity to the variable heavy and light polypeptide sequences of SEQ ID NO: 746 and 747 respectively.

3. The method of claim 1 wherein the isolated antibody comprises a variable heavy and/or variable light polypeptide having at least 95% sequence identity to the variable heavy and light polypeptide sequences of SEQ ID NO: 746 and 747 respectively.

4. The method of claim 1 wherein the isolated antibody comprises a variable heavy and/or variable light polypeptide having at least 96-99% sequence identity to the variable heavy and light polypeptide sequences of SEQ ID NO: 746 and 747 respectively.

5. The method of claim 1 wherein the isolated antibody comprises a variable heavy and/or variable light polypeptide identical to the variable heavy and light polypeptide sequences of SEQ ID NO: 746 and 747 respectively.

6. The method of claim 1 , which further includes the administration of another drug or biologic used for the treatment of arthritis.

7. The method of claim 6 , wherein said other drug or biologic is selected from corticosteroids, other anti-inflammatory agents, anti-malarial drugs, anticoagulants, ACTH, other immunosuppressants, methotrexate, cyclophosphamide, belimumab and other immunomodulatory antibodies.

8. The method of claim 7 , wherein said other drug or biologic is a corticosteroid.

9. The method of claim 7 , wherein said other drug or biologic is methotrexate or cyclophosphamide.

Assignees

• Immunext Inc
• Janssen Pharmaceutica Nv

Inventors

• Carriere Catherine
• Molloy Michael
• Rothstein Jay
• Snyder Linda
• Powers Gordon

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K38/16 Primary

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• C07K14/705

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title

• C07K16/42

  against immunoglobulins · CPC title

• C07K16/46

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title